AmTech Starts Pfizer (PFE) at Buy
More News related to PFE
- Court in Denmark Upholds Two Lipitor Patents, Prevents Launch of Ranbaxy Generic Product before November 2011
- Bristol-Myers (BMY) and Pfizer (PFE) Provide Update on Apixaban Clinical Development Program - Primary Endpoint Not Met
- Bristol-Myers Squibb and Pfizer Provide Update on Apixaban Clinical Development Program
- Pfizer (PFE) Decides Not to Launch Phase III Study for Glaucoma Treatment in Asia - Reuters
- Barr Pharmaceuticals (BRL) Receives Approval for Generic Aredia
More News related to New Coverage
- Raymond James Downgrades Williams-Sonoma (WSM) to Market Perform
- Raymond James Downgrades FPIC Insurance (FPIC) to Market Perform
- Bernstein Downgrades Novo Nordisk (NVO) to Underperform
- Robert Baird Downgrades S.Y. Bancorp (SYBT) to Neutral
- Matrix USA Rating Changes 8/29
American Technology Research initiates coverage on Pfizer (NYSE: PFE) with a Buy rating.
Pfizer, Inc. engages in the discovery, development, manufacture, and marketing of prescription medicines for humans and animals worldwide.
Related Categories
New CoverageStocks Mentioned
-0.16Related Entities
Sign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
